The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2020 | Understanding CLL pathogenesis by assessing clonotypes
Andreas Agathangelidis, PhD, Center for Research and Technology Hellas, Thermi, Greece, discusses how clonotypes can be used to assess biological and clinical roles in chronic lymphocytic leukemia (CLL) and how they affect disease development. By scanning healthy, preleukemic individuals the deterioration of the immune system can be assessed. The immunoglobulin sequences present in CLL were found in very few of the healthy individuals scanned. They were only found in immature B-cells, suggesting that, in healthy individuals, the immune system excludes these sequences in mature B-cells that could threaten homeostasis. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
